These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 26398165)
1. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine. Uppugunduri CR; George M J Cardiovasc Pharmacol; 2016 Feb; 67(2):191-2. PubMed ID: 26398165 [No Abstract] [Full Text] [Related]
2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value. Tice JA; Kazi DS; Pearson SD JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572 [No Abstract] [Full Text] [Related]
4. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target]. Guijarro C; Ruilope LM Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275 [No Abstract] [Full Text] [Related]
5. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848 [No Abstract] [Full Text] [Related]
6. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors]. Avci A; Demir K; Altunkeser BB Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363 [TBL] [Abstract][Full Text] [Related]
7. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
8. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program]. Lettino M G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756 [No Abstract] [Full Text] [Related]
9. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia. Ascaso JF Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861 [No Abstract] [Full Text] [Related]